zimmer biomet stock overview

This comprehensive guide explains Zimmer Biomet stock (ZBH): what the company does, how the shares trade, key financial and market data, risks, governance, and where investors can find up-to-date q...

2024-07-13 11:39:00

By Blockchain Nomad

Article rating

4.2

116 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zimmer Biomet Holdings, Inc. (ZBH) — Stock

Brief lead: Zimmer Biomet stock (ZBH) is the publicly traded common equity of Zimmer Biomet Holdings, Inc., a global medical‑device company focused on orthopedic reconstructive implants, surgical robotics and related digital solutions. The shares trade primarily on the New York Stock Exchange in U.S. dollars and are followed by investors looking for exposure to orthopedics and healthcare equipment.

Introduction

This article centers on zimmer biomet stock for readers who want a thorough, beginner‑friendly reference on the company, its shares, and where to find up‑to‑date market data and filings. You will learn how to identify ZBH in the market, where to check historical performance and valuation metrics, what risks to watch, and practical notes on trading and custody — with pointers to authoritative data sources. The guide also highlights Bitget features for custody and trading where relevant.

Company background

Zimmer Biomet Holdings, Inc. is a global medical‑technology company specializing in musculoskeletal healthcare. Its product portfolio centers on orthopedic reconstructive implants (hips, knees, shoulders), trauma and extremities, dental and spine solutions, and an expanding set of robotic, digital‑planning and intraoperative technologies that complement implant businesses.

Origins and headquarters: Zimmer Biomet traces roots to Zimmer, Inc. (founded mid‑20th century) and Biomet, Inc. (founded in 1970s). The modern Zimmer Biomet formed after a significant merger in 2015 when Zimmer Holdings completed the acquisition of Biomet, creating one of the world’s largest orthopedics firms. The company is headquartered in Warsaw, Indiana, USA.
Major milestones: Key corporate milestones include the 2015 Zimmer‑Biomet merger, several targeted acquisitions to add robotics and digital capabilities, divestitures and portfolio rationalizations, and continuous investment in R&D for implant design and surgical workflows.
Core markets and customers: Zimmer Biomet serves hospitals, ambulatory surgery centers, dental clinics and physicians globally. Revenue drivers include procedure volumes, product mix (reconstructive implants vs. instruments), new product adoption (e.g., robotic systems), and geographic exposure (North America, Europe, Asia Pacific, emerging markets).

Sources and filings provide deeper timelines and merger details; investors typically consult the company’s investor relations materials for official history and milestone timelines.

Stock identification and listings

Ticker symbol and exchanges

Primary ticker: ZBH. The shares trade on the New York Stock Exchange (NYSE) in U.S. dollars.
Secondary listings: Zimmer Biomet historically has maintained listings or trading arrangements in other jurisdictions (for example, listings on Swiss exchanges in the past). Trading currency and availability depend on the exchange and market hours.

CUSIP, ISIN and transfer agent

CUSIP: 98956P102 is the CUSIP assigned to Zimmer Biomet common stock for U.S. securities identification.
ISIN: The U.S. ISIN is based on the CUSIP (investors may confirm the precise ISIN for cross‑border clearing via the company’s transfer agent or SEC filings).
Transfer agent: Computershare is the transfer agent historically used for Zimmer Biomet shareholder services (record keeping, dividend disbursement, direct stock purchase and dividend reinvestment plan administration). Consult the company investor relations for the latest transfer agent contact details.

Share structure and corporate actions

Shares outstanding and float: Zimmer Biomet’s total shares outstanding and public float change with buybacks, issuances and corporate actions. The exact share count and diluted shares are published in quarterly reports (Form 10‑Q) and the annual report (Form 10‑K).
Stock splits and corporate actions: Historical splits, if any, and recent capital allocation decisions (share repurchases, issuances connected to acquisitions or employee compensation) are described in SEC filings and investor presentations. Investors should review the latest 10‑K/10‑Q to confirm current outstanding shares and any planned actions.

Market data and trading information

Price and market capitalization

Where to find live price and market cap: Real‑time price quotes, market capitalization and currency‑denominated values for zimmer biomet stock are available from market data providers and the company’s investor relations summary. Market cap = share price × shares outstanding; because both vary, market capitalization fluctuates during trading hours.
Common reference points: Investors commonly reference previous close, intraday high/low, 52‑week high/low and adjusted historical prices (which reflect dividends and splits). For precise and current numbers, use a real‑time feed from your brokerage platform or an authoritative financial portal.

As of 2024‑06‑01, according to company investor relations summaries and financial portals, ZBH market metrics were published on summary pages; readers should confirm the live quote before acting.

Trading volume, liquidity and float metrics

Average daily volume: Average trading volume indicates how liquid zimmer biomet stock is on a typical day. Traders compare average daily volume to recent daily volume to spot unusual activity.
Volume spikes: Sudden spikes often occur around earnings releases, FDA decisions, major mergers/acquisitions news, or analyst coverage adjustments.
Float and % short interest: Public float and reported short interest (expressed as a percentage of float and/or days to cover) are useful to estimate potential short‑squeeze risk and investor sentiment. These metrics are reported regularly by exchanges and data providers.

Investors should check volume and short‑interest reports from the exchange and major data aggregators for specific numeric values as of the date of interest.

Key valuation metrics

Commonly reported valuation and performance metrics for zimmer biomet stock include:

Price/Earnings (P/E) ratio: Compares current price to trailing or forward earnings per share.
Price/Sales and Price/Book: Useful when earnings are volatile or to compare to peers.
Enterprise Value/EBITDA: A capital‑structure‑neutral metric for comparing operational performance.
Dividend yield: Annual dividends per share divided by current share price, important for income‑oriented investors.

These metrics should be considered relative to the medical‑devices sector and specific competitors. Financial portals and research platforms provide both trailing and forward versions of these metrics; always confirm whether metrics are adjusted for nonrecurring items.

Historical performance

Zimmer Biomet’s historical stock performance is shown via multi‑year charts that display price appreciation, dividends, and adjusted returns. Historical series from vetted providers (e.g., Macrotrends, Morningstar) include adjusted closing prices that account for splits and dividends to give an accurate long‑term return picture.

All‑time high/low and 52‑week range: These reference points help contextualize current price levels. Data providers publish the 52‑week high and low as a quick snapshot.
Long‑term trends: Investors often examine 5‑ and 10‑year price trends and overlay corporate events (mergers, major FDA approvals, large acquisitions) to understand drivers of performance.

As of 2024‑06‑01, adjusted historical charts were available from sources such as Macrotrends and company filings; check those sources for up‑to‑date adjusted series.

Financials and operating results

Revenue and profitability

Where to find figures: Recent revenue, gross profit, operating income and net income trends are in the company’s quarterly earnings releases, the annual 10‑K, and financial‑data platforms.
Revenue drivers: Procedure volumes (elective orthopedic surgeries), geographic recovery patterns, new product launches, and pricing pressures affect revenue. Adoption of robotics or digital systems can shift long‑term margins by introducing higher‑margin recurring revenue streams (services, software licensing, disposables).
Margins: Gross margin and operating margin trends illustrate how product mix, manufacturing costs and R&D investments affect profitability.

Management commentary during earnings calls often clarifies whether margin movements are driven by mix, commodity costs, or investments in growth initiatives.

Balance sheet and cash flow

Key balance‑sheet items and cash‑flow dynamics investors monitor for zimmer biomet stock include:

Net debt position: Total debt minus cash and equivalents is a principal measure for leverage assessment.
Working capital and inventory: For product companies, inventory levels and supply‑chain timing can materially affect working capital and free cash flow.
Capital expenditures and free cash flow: Capital allocation decisions — acquisitions, capex for manufacturing or R&D, dividends and buybacks — are assessed against free cash flow generation.

Quarterly filings and the cash‑flow statement present operating cash flow, investing cash flow, and financing activities; these documents show how management funds acquisitions and shareholder returns.

Earnings releases and guidance

Earnings cadence: Zimmer Biomet reports quarterly financial results and files an annual 10‑K. Each quarter, the company typically provides revenue and EPS results and may issue guidance for the upcoming quarter or full fiscal year.
Management commentary: Earnings releases and conference calls provide management’s view on procedure volumes, product backlog, margin expectations, and regulatory or supply constraints.

As of 2024‑06‑01, recent quarterly releases and earnings slides were available through the company’s investor relations site and SEDAR/SEC filings; investors should reference those sources for the most recent guidance and management commentary.

Dividends, shareholder returns and plans

Dividend policy and history

Dividend payments: Zimmer Biomet has historically paid regular quarterly dividends. Dividend yield and recent payment dates are reported in dividend history summaries on financial portals and in the investor relations dividend history.
Changes and sustainability: Dividend sustainability is evaluated versus free cash flow and capital allocation priorities. Management may adjust dividends in response to changing cash‑flow outlooks or strategic needs.

Investors should verify the declared dividend per share and record/ex‑dividend/payment dates from the company’s dividend announcements.

Dividend reinvestment plans and direct purchase

Direct purchase and DRIP: The company’s transfer agent (Computershare) typically administers a Customer Investment Plan (CIP) or DRIP, allowing retail investors to buy shares directly, enroll in automatic dividend reinvestment, or make optional cash investments subject to plan terms.
How to enroll: Enrollment details (minimum initial investment, reoccurring purchase options, fees) are listed in the transfer agent materials and on the investor relations site.

Retail investors who prefer self‑custody or integrated wallets may also consider brokerage custody; for crypto‑native investors seeking integrated services, Bitget provides custody and trading solutions alongside wallet products.

Analyst coverage and market sentiment

Analyst ratings and consensus: Sell/hold/buy ratings and consensus price targets for zimmer biomet stock are published by banks and independent research firms and aggregated by major financial portals. These summaries help gauge market sentiment and expectations but should not substitute for independent analysis.
Sources of commentary: Major equity research desks, healthcare sector analysts, and financial news outlets publish notes ahead of earnings, after regulatory news, or around significant corporate actions.

As of 2024‑06‑01, multiple brokerages and independent analysts covered ZBH; the consensus outlook varies with assumptions on procedure recovery, pricing environment, and success of product launches.

Major shareholders and institutional ownership

Institutional ownership: Large holders of zimmer biomet stock typically include mutual funds, pension funds, ETFs and other institutional investors. Institutional ownership levels affect liquidity and can influence corporate governance dynamics.
Why it matters: High institutional ownership may reduce free float and increase stability, while concentrated ownership by a few funds can impact trading dynamics around rebalancing events.

Public filings (13F filings and proxy statements) provide visibility into institutional holders and recent changes in ownership.

Regulatory, legal and operational risks

Zimmer Biomet operates in a highly regulated industry. Key categories of risk for zimmer biomet stock include:

Regulatory approvals and clearances: Device approvals (e.g., FDA clearances) and post‑market surveillance are core to the business. Delays or denials can materially affect new product revenue prospects.
Quality and manufacturing controls: Recalls, manufacturing deviations, and product quality issues can lead to litigation, regulatory action, and reputational harm.
Reimbursement and purchasing dynamics: Changes in hospital procurement practices, reimbursement policy shifts, and competitive tendering can alter demand and pricing.
Litigation and investigations: Device manufacturers sometimes face product liability litigation or government investigations; material legal expenses or settlements can impact earnings.
Supply‑chain and integration risks: Acquisitions intended to broaden robotics or digital offerings carry integration risk; supply constraints for components can limit production and sales.

As of 2024‑06‑01, regulatory and litigation disclosures were included in the company’s 10‑K and subsequent 8‑K filings; investors should review recent filings for current contingencies.

Corporate governance and investor relations

Board and management

Governance structure: Zimmer Biomet maintains a board of directors responsible for oversight, with committees for audit, compensation and governance. Key executives (CEO, CFO, heads of major business units) drive strategy execution.
Leadership impact: Management decisions on R&D prioritization, acquisition strategy and capital allocation materially influence long‑term performance and risk profile.

Investors evaluate management track records for integration, cost control and innovation adoption when assessing company prospects.

Investor relations resources

SEC filings and reports: The investor relations site provides access to the annual report (Form 10‑K), quarterly reports (Form 10‑Q), and current reports (Form 8‑K), plus earnings presentations, transcripts and shareholder FAQs.
How to contact IR: Contact information for investor relations, directions on how to request filings, and details on attending earnings calls are published on the IR page and in regulatory filings.

For the most accurate and up‑to‑date documents, use the company’s investor relations materials and the SEC EDGAR repository.

Comparative peers and sector context

Zimmer Biomet operates in the medical devices and healthcare equipment sector. Primary competitors and comparable companies include large diversified medical‑technology firms and specialty orthopedics players. Benchmark peers often considered for valuation and operational comparison include companies that focus on orthopedics, surgical robotics, or diversified device markets.

When benchmarking zimmer biomet stock to peers, analysts compare revenue growth, margins, R&D intensity, return on invested capital, and valuation multiples (P/E, EV/EBITDA).

How to trade and custody considerations

How to buy/sell: Investors buy zimmer biomet stock through brokerage accounts that provide NYSE access. Orders can be market, limit, stop, or more advanced order types depending on the platform.
Margin and shorting: Margin availability and shorting rules depend on the brokerage. Traders should confirm margin requirements and short‑interest reporting if they plan to short ZBH.
ADR and foreign listings: If you encounter cross‑listed or foreign‑traded forms of the shares, verify settlement details, currency exposure and custody implications. Most retail investors buy the primary NYSE listing in USD.
Custody and wallets: For investors who want consolidated asset management, Bitget offers custody and wallet services that can be used alongside brokerage trading. For equity custody, verify segregation and insurance protections provided by the custody platform.

Practical note: Always confirm settlement cycles (T+2 for U.S. equities) and dividend treatment with your broker or transfer agent.

References and data sources

The following sources are commonly used to verify pricing, financials and corporate data for zimmer biomet stock:

Company investor relations materials (earnings releases, annual and quarterly reports)
SEC filings (Form 10‑K, 10‑Q, 8‑K)
Macrotrends — historical price series and adjusted close data
Yahoo Finance — quote pages and summary statistics
Morningstar — company profiles and valuation metrics
CNBC and CNN Markets — company overview and news coverage
The Motley Fool and MarketWatch — company analyses and market data snapshots
Brokerage research and analyst reports (for consensus estimates and ratings)

As of 2024‑06‑01, these sources provided the referenced datasets and commentary. For real‑time quotes and the latest filings, consult the company’s investor relations pages and official SEC filings.

External links

Zimmer Biomet investor relations (search the company IR page for filings and presentations)
SEC EDGAR repository for Zimmer Biomet filings (10‑K, 10‑Q, 8‑K)
Financial data portals (for live quotes, historical charts, and analyst consensus)

Practical checklist for investors researching zimmer biomet stock

Confirm the current price, market cap and shares outstanding from a live market feed.
Review the most recent Form 10‑K and quarterly 10‑Q for financial statements and risk disclosures.
Listen to the latest earnings call transcript for management’s commentary on procedure volumes and product adoption.
Check recent FDA or regulatory updates that may affect new product launches.
Verify dividend declarations and record/ex‑dividend dates via the transfer agent notice.
Evaluate analyst consensus and the range of price targets for sensitivity to assumptions.
If trading, verify custody, settlement timing and custody protections offered by your chosen platform; consider Bitget services for custody or wallet integration where appropriate.